N2OFF Completes Merger with MitoCareX Bio to Expand into Cancer Drug Discovery Targeting Mitochondrial Proteins

N2OFF, Inc. a cleantech company investing in solar energy assets based on the RTB (Ready to Build) business model, recently announced the closing of the ...

October 31, 2025 | Friday | News
IN8bio Adds The Ohio State University as New Clinical Site for INB-100 Phase 1 Trial

IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies for cancer and autoimmune dise...

October 30, 2025 | Thursday | News
Samsung Bioepis to Assume Full Commercial Control of BYOOVIZ in Europe by January 2026

  Samsung Bioepis will assume full commercial responsibility for BYOOVIZ®(ranibizumab) upon full transition of Biogen’s commercializa...

October 30, 2025 | Thursday | News
Zag Bio Launches with $80 Million Financing to Pioneer Thymus-Targeted Therapies for Autoimmune Diseases

Discovery and development of the first systemic therapeutics to deliver self-antigens directly to the thymus to harness the body’s natural mechanis...

October 29, 2025 | Wednesday | News
BD Showcases Next-Generation Drug Delivery and RFID Traceability Solutions at CPhI 2025

 BD (Becton, Dickinson and Company), a leading medical technology company, will feature the next generation of drug delivery and traceability s...

October 28, 2025 | Tuesday | News
Chromatin Bioscience and Purespring Therapeutics Partner to Develop Cell-Selective Synthetic Promoters for Next-Generation Gene Therapies

Chromatin Bioscience is pleased to announce an ongoing research collaboration with Purespring Therapeutics, a precision nephrology company leading the de...

October 28, 2025 | Tuesday | News
Vas Narasimhan Calls USD 12 Billion Avidity Acquisition a Defining Move to Advance Novartis Mission in Neuromuscular Disease Treatment

Transaction strengthens neuroscience franchise for Novartis with three late-stage programs that address genetic neuromuscular diseases Advances the No...

October 27, 2025 | Monday | News
Zai Lab Reports 68% Response Rate for DLL3-Targeted ADC Zocilurtatug Pelitecan in Second-Line Small Cell Lung Cancer

- Robust responses observed in heavily pre-treated patients with a 68% ORR for 1.6 mg/kg in second-line setting -Compelling activity in patients with ...

October 27, 2025 | Monday | Reports
SK pharmteco Invests $6.1 Million to Expand U.S. Peptide Manufacturing Capabilities in California

SK pharmteco, a global contract development and manufacturing organization (CDMO), announced today a $6.1 million investment in its Rancho Cordova facili...

October 24, 2025 | Friday | News
Abzena Grants Orion Exclusive License to CHAb™-Designed Antibody Targeting High-Unmet-Need Cancer

Abzena, the leading end-to-end integrated CDMO for complex biologics and bioconjugates, announced that Orion has obtained an exclusive focused commercial...

October 24, 2025 | Friday | News
Syngene Strengthens India’s Biologics Leadership with New GMP Bioconjugation Suite in Bengaluru

Syngene International, a global contract research, development and manufacturing organization (CRDMO), is adding a GMP bioconjugation suite at its commerci...

October 23, 2025 | Thursday | News
ProImmune Expands UK Operations with New Global Headquarters at Oxford’s Oasis Park

Move follows ProImmune’s recent acquisition of Oasis Park a 70,000 sq ft Business and Light Industrial Park in Oxford, UK Increased operationa...

October 23, 2025 | Thursday | News
BriaCell Partners with Memorial Sloan Kettering to Accelerate Development of Next-Generation Personalized Immunotherapy

Collaboration with MSK’s Therapeutics Accelerator Program includes manufacturing, IND and clinical development support of the Bria-OTS+™ pl...

October 22, 2025 | Wednesday | News
Agarose Bead Technologies Marks 25 Years with $10 Million Expansion and Global Growth Strategy

Agarose Bead Technologies (ABT), a leading manufacturer of high-quality agarose resins has announced plans for further expansion, reinforcing its positio...

October 22, 2025 | Wednesday | News

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
Processing...
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2025 Biopharma Boardroom. All Rights Reserved.

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close